Synta Pharmaceuticals has planned or already begun three new multicenter, randomized trials, supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, to evaluate ganetespib in combination with chemotherapy in first-line treatment of patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). The trials are being conducted under the UK National Cancer Institute (NCRI) Haematological Oncology Study Group with investigators in Denmark, France, New ...